Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
New RAF-targeted therapeutic shows early promise against tumours with BRAF and RAS mutations

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 27.04.16
Views: 1415

Dr Jayesh Desai - Royal Melbourne Hospital, Melbourne, Australia

Dr Jayesh Desai speaks with ecancertv at AACR 2016 about his phase Ia trial with RAF-dimer inhibitor BGB283.

BGB283 also acts an EGFR inhibitor, and may have effect on downstream RAS expression. 

Dr Desai's trial reports results from numerous tumour types from patients all expressing RAF/BRAF mutations, using BGB283 as a single agent.

With phase II trials moving ahead, more details can be found in the supporting news article located here. 

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation